Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03430063
Title A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Regeneron Pharmaceuticals

lung non-small cell carcinoma


Cemiplimab + Ipilimumab


Age Groups: senior | adult
Covered Countries USA | FRA | ESP | DEU | BEL

Additional content available in CKB BOOST